Loading fund…
Loading fund…
| Returns | 1D | 1M | 3M | YTD | 1Y | 3Y | 5Y | MAX |
|---|---|---|---|---|---|---|---|---|
| Total return | ▼ −0.8% | ▲ +3.0% | ▼ −3.6% | ▲ +2.9% | ▲ +5.2% | — | — | ▲ +41.0% |
| Peer average | — | — | — | — | — | — | — | — |
| S&P 500 · VOO | ▼ −0.5% | ▼ −2.3% | ▼ −2.2% | ▲ +11.2% | ▲ +11.8% | ▲ +89.5% | ▲ +77.1% | — |
Under typical conditions, this investment vehicle commits a predominant portion—no less than 95%—of its total assets to American Depositary Receipts (ADRs) representing GSK plc. It notably avoids direct investment in the company's underlying shares. Such a focused approach means the fund operates as a non-diversified portfolio.
Distribution yield and SEC yield use different methodologies. Payouts may include income, capital gains, or return of capital.
| Ex-date | Pay date | Per share |
|---|---|---|
| 2026-06-16 | 2026-06-23 | $0.93 |
| 2026-03-16 | 2026-03-23 | $0.36 |
| 2025-12-16 | 2025-12-24 | $0.79 |
Estimated annual expense excludes trading costs and assumes constant assets. Fee waivers and fund costs can change.
Historical risk measures describe past behavior and do not predict future returns.
Hear the strategy from the people behind GSKH.